fashion -WSS

fashion

author：entertainment 2025-09-03 07:44:44 - browse：7

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Plane’s emergency slide plummets from sky, hits Chicago home

focus

WSS

Ebola public health emergency is over, WHO declares

Antibody drugs appear effective. Now can we make enough of them?

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

Norman Reedus' Daryl Dixon

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

Vermont grapples with historic flooding as more rainstorms head for Northeast

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Watch the official trailer for 'Ahsoka' series

The cancer drug shortage isn’t new — and neither are the solutions

Superbugs, antibiotic resistance get scrutiny in congress

In age of alternative facts, a scholarly course on calling out crap

Why some people catch Covid but never get sick

Continuity nursing helped my family in our darkest PICU moments

India sets sights on home

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

hotspot

Cuban government calls US nuclear submarine stop a 'provocative escalation'

Britney Spears to release memoir, 'The Woman In Me,' later this year

Britney Spears to release memoir, 'The Woman In Me,' later this year

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

Why some people catch Covid but never get sick

Blinken talks high

focus

focus

focus

hotspot